Amphastar Pharmaceuticals AMPH Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Geography | ||||||
| CN | $5.59M+39.0% | $3.18M-26.6% | $4.45M-1.2% | $2.75M-46.7% | $4.02M-16.0% | |
| FR | $37.07M+42.4% | $35.28M+76.9% | $33.89M+203% | $28.73M+246% | $26.03M+474% | |
| US | $677.87M-3.2% | $681.42M-3.7% | $684.96M-3.2% | $691.2M-1.2% | $700.61M+5.1% | |
| Non-Current Assets by Geography | ||||||
| CN | $438.66M+5.1% | $440.58M+10.0% | $438.41M+14.0% | $431.78M+16.3% | $417.22M+14.4% | |
| FR | $146.47M+2.9% | $146.14M+1.5% | $143.58M-2.5% | $143.79M-2.6% | $142.31M-5.4% | |
| US | $855.76M-36.8% | $829.02M-56.6% | $824.65M-56.4% | $805.07M-67.5% | $1.35B-45.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Amphastar Pharmaceuticals break its business down?
- Amphastar Pharmaceuticals (AMPH) reports revenue by business across 2 parts — Finished Pharmaceutical Products and Pharmaceutical Products. Each is extracted from the segment footnotes and tracked over time.
- Where does Amphastar Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Amphastar Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
